Haemonetics Corporation reported second quarter fiscal 2026 revenue of $327 million, a decrease of 5.0 percent compared to the prior year period. Year-to-date revenue was $649 million, also down 5.0 percent. Organic revenue decreased by 1.8 percent in the quarter and 0.7 percent year-to-date. Excluding CSL, organic revenue increased by 9.4 percent in the quarter and 11.1 percent year-to-date. Earnings per diluted share were $0.81 for the quarter and $1.51 year-to-date. Adjusted earnings per diluted share were $1.27 for the quarter and $2.36 year-to-date. The company raised its total company fiscal 2026 guidance.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.